Nelson Advisors: The Ascendance of Founder Bankers, Macroeconomic Dislocation and the Liquidity Imperative in European HealthTech, MedTech, Health AI
Macroeconomic Dislocation and the Liquidity Imperative in European Healthtech
The European healthcare technology sector has entered a protracted period of structural realignment, precipitated by the breakdown of the historical venture capital funding escalator. Between 2020 and 2021, zero-interest-rate monetary policies and temporary pandemic tailwinds channeled speculative capital into early-stage digital health platforms, creating inflated entry valuations and subsidising unsustainable operational burn rates.
The subsequent tightening of macroeconomic conditions and rapid increases in the cost of capital revealed the fragility of models detached from cash generation. By late 2024, invested capital in European Series B healthcare rounds fell by approximately 84% relative to peak 2021 levels. Simultaneously, the average holding interval between funding rounds expanded beyond 774 to 1,000 days, forcing approximately 37% of early-stage financing events to take the form of internal bridge rounds that heavily encumbered capitalization tables.
This capital contraction established what market practitioners describe as the "Series A Off-Ramp". Startups that built operational footprints around the presumption of successive, dilutive equity rounds discovered that growth-stage capital was unavailable without proven unit economics. Compounding this funding bottleneck, public equity markets became virtually inaccessible for unprofitable European technology assets. Institutional public equity investors implemented stringent underwriting criteria demanding demonstrable EBITDA margins, non-GAAP operating profitability, and strict capital discipline, shutting down the traditional initial public offering (IPO) path for all but the largest and most mature scale-ups.
At the fund level, liquidity friction has created intense pressure for both venture capital and private equity sponsors. Maturing venture funds, approaching the conclusion of standard ten year commitment vehicles, face increasing demands from institutional limited partners (LPs) to generate distributed to paid in capital (DPI) before committing to successor vintages. Concurrently, mid market private equity sponsors, navigating extended portfolio holding periods, require structured realisation events to recapitalise platforms.
The acute valuation spread between historical entry marks and prevailing market-clearing levels has necessitated alternative transaction architectures. To generate liquidity, facilitate strategic exits, and restructure distressed balance sheets, founders and institutional sponsors are shifting away from clean, all-cash trade sales, deploying instead asset based transactions, share-for-share venture consolidations, private equity roll ups and structured secondary vehicles.
The Emergence and Advisory Anatomy of the Founder Banker
The intricate mechanics of executing transactions within the European healthcare technology environment have exposed structural deficiencies within traditional corporate finance advisory models. Historically, the advisory landscape was divided between generalist technology investment bankers, who analysed digital health assets through the lens of horizontal software metrics like customer acquisition cost (CAC), lifetime value (LTV) and annual recurring revenue (ARR) retention and traditional life sciences corporate financiers focused on balance-sheet underwriting, biopharmaceutical trial pipelines, and clinical real estate.
This structural divide generated a pronounced "Translation Gap". Horizontal technology bankers consistently underestimated the institutional resistance within European healthcare systems, misunderstanding lengthy National Health Service (NHS) procurement pipelines, decentralised hospital tendering procedures, and complex reimbursement mechanisms such as Germany's DiGA or France's PECAN frameworks. Conversely, traditional healthcare bankers lacked technical fluency in modern software architectures, data engineering, clinical artificial intelligence interpretability and seamless integration into legacy Electronic Patient Record (EPR/EHR) environments.
Advisory Category | Representative Firms | Core Deal Range (EV) | Typical Leadership Profile | Primary Value Proposition |
Entrepreneurial Architects (Founder Bankers) | Nelson Advisors, HGM Advisory, Think.Health | €25M – €250M | Former HealthTech founders, scale-up operators, clinical scientists, corporate financiers | Operational empathy, clinical workflow positioning, hands-on partner immersion, cross-border regulatory structuring |
Tech Translators | Clipperton, Arma Partners | €50M – €500M+ | Technology growth bankers, enterprise software corporate finance specialists | Applying enterprise software valuation metrics to clinical assets; bridging the mid-market VC-to-PE transition |
Pure-Play Specialists | ConAlliance, Van Lanschot Kempen | €10M – €500M | Healthcare economists, physicians, regulatory/legal scholars, life sciences bankers | Immersion in hospital infrastructure, academic networks, MDR compliance moats, biotech/diagnostics capital raises |
Mid-Market Matchmakers | Rothschild & Co, Houlihan Lokey, Lincoln International, Deloitte | €100M – €1B | Career mid-market investment banking professionals | Broad private equity sponsor coverage, high deal volume, structured auction management, roll-up syndication |
Scientific Powerhouses (Bulge Bracket) | Goldman Sachs, J.P. Morgan, Jefferies | €1B+ | Bulge-bracket career bankers; medical doctors (MDs) and PhDs leading life sciences diligence | Sovereign capital access, balance-sheet underwriting, mega-cap transformative cross-border M&A |
Founder bankers have stepped into this void. These advisors are former healthtech entrepreneurs, clinical operators, and corporate finance practitioners who have built, scaled, and exited healthcare ventures prior to entering M&A advisory. Rather than executing rigid, transactional auction mandates, founder bankers provide operational empathy and technical depth, establishing prolonged corporate development advisory relationships that prepare businesses for acquisition long before an engagement is launched. Their direct experience managing cash runways, clinical trial validations, medical device audits, and complex board dynamics enables them to facilitate difficult discussions regarding valuation resets and capitalisation structure recaps with credibility.
Specialist boutique advisory firms exemplify this trend. Nelson Advisors, founded by serial digital health entrepreneur Lloyd Price (co-founder of patient-engagement platform Zesty, which was integrated into the NHS and acquired by Induction Healthcare) and former Credit Suisse investment banker Paul Hemings, combines operational scale-up experience with institutional corporate finance execution.
In a similar vein, HGM Advisory operates through tailored teams led by founders such as Dr. Andreas Schmidt, who built and exited single cell sequencing pioneer Proteona to Singleron Biotechnologies. In the DACH region, Think.Health, guided by former Labor Berlin chief executive Dr. Florian Kainzinger, merges M&A advisory with clinical laboratory infrastructure networks. Meanwhile, ConAlliance approaches the market through an academic and clinical lens, utilizing partners such as Prof. Dr. Dr. Ulrich Hemel and Prof. Christian Langbein to advise family owned medical device manufacturers and navigate European Medical Device Regulation (MDR) frameworks. In the software growth tier, Clipperton bridges VC and PE landscapes, advising clinical workforce management platform Hublo on its growth investment from Five Arrows and counseling Carlyle on its acquisition of Inova Software.
Alternative Transaction Structuring and Financial Engineering
In a market defined by constrained primary venture funding, transactional liquidity is achieved primarily through alternative legal and financial structures engineered to bridge wide valuation gaps.
Venture to Venture (V2V) Share for Share Mergers
Venture to venture consolidation has become a primary liquidity and continuity mechanism for European early to mid stage digital health platforms. Across 2025 and 2026, strategic M&A has driven roughly 95% of all digital health exits, with V2V consolidations accounting for approximately 75% of total acquisition volume in the first half of 2025 alone. These transactions are predominantly executed as share-for-share exchanges, allowing late stage scale-ups to deploy their equity currency to absorb early stage product innovations, regulatory clearances, and specialised technical teams without depleting liquid cash reserves.
A clear example of this dynamic is the September 2024 acquisition of primary care triage platform eConsult by Huma Therapeutics. Executed as a pure share for share transaction, the merger enabled Huma to consolidate eConsult's clinical footprint across 1,800 NHS primary care practices directly into the Huma Cloud Platform, expanding its patient pipeline from initial triage to remote monitoring and hospital at home workflows. For eConsult's venture backers and founders, rolling their holdings into Huma's capitalisation structure exchanged an illiquid, capital constrained point product for a shareholding in an advanced aggregator with cross-border reach and eventual public listing prospects.
Market leaders like Doctolib have similarly executed programmatic consolidation playbooks. Doctolib expanded beyond pure play booking software into practice management and clinical artificial intelligence through acquisitions of platforms like MonDocteur and conversational AI provider Aaron.ai. However, founder bankers advising on V2V consolidations must structure transactions within an increasingly complex competition framework.
Following the European Court of Justice's Towercast precedent, the French Competition Authority issued a €4.7 million fine against Doctolib related to its MonDocteur transaction, establishing that antitrust authorities can investigate acquisitions below mandatory revenue thresholds if the acquirer holds a dominant market position. Founder bankers evaluate these antitrust thresholds during initial pipeline design, directing targets toward non-dominant regional consolidators or private equity platforms when local category leaders present significant merger clearance liabilities.
Private Equity Platform Consolidations and Buy and Build Strategies
Confronting hospital CIO fatigue generated by disparate single-utility software point solutions, mid-market private equity sponsors are descending downstream into Series A and Series B healthtech. Sponsors utilize buy-and-build strategies to aggregate clinical point solutions into unified enterprise platforms across sectors like dental management, fertility care, ophthalmology, and clinical workforce operations. Notable executions include Five Arrows' investments in healthcare workforce platform Hublo and cardiac AI monitoring specialist Implicity, both structured to assemble broader clinical workflow operating systems.
A central technical function of founder bankers in PE roll-ups involves modeling and negotiating rollover equity structures. Financial sponsors typically mandate that selling founders and venture backers roll over between 10% and 30% of their equity value into the acquiring NewCo entity, ensuring strategic alignment and offering exposure to future platform recapitalisations.
Founder bankers must rigorously audit the underlying capital distribution waterfall of the sponsor’s vehicle to determine whether this rollover equity holds genuine economic value. While a headline enterprise valuation may seem attractive, common rollover equity is frequently subordinated beneath senior leverage, cumulative preferred return hurdles, and management incentive pools.
Capital Waterfall Tier | Capital Instrument / Component | Standard Market Parameters | Priority, Hurdle, and Distribution Mechanics | Structural Impact on Founder / Rollover Common Equity |
Layer 1: Senior Debt | Third-party bank debt / Unitranche facilities | 40% – 60% of total Enterprise Value | Repaid with absolute senior priority at exit, including accrued amortization and financing fees | Dollar-for-dollar reduction of net distributable equity value available to subsequent share classes |
Layer 2: Sponsor Preferred Equity | Sponsor preferred shares / shareholder loans | Equivalent to 70% – 90% of sponsor equity check | 100% capital return plus an 8% to 10% annual cumulative dividend hurdle prior to any junior distribution | Dilutive in flat or modest secondary exits; preferred dividend accrual can completely absorb the remaining equity proceeds |
Layer 3: Option Pool (MIP) | Management Incentive Plan equity awards | 10% to 15% fully diluted post-closing equity carve-out | Carved out post-closing to incentivize incoming platform executive management; vests on performance/time milestones | Directly dilutes the common equity pool, reducing the effective ownership stake of rollover shareholders |
Layer 4: Common Equity | Founder rollover common shares & Sponsor common co-investment | Remaining net equity value pool | Distributed strictly pro-rata based on ordinary share percentages after satisfaction of Layers 1 through 3 | Asymmetric returns; completely dependent on platform enterprise value outstripping senior debt and preferred hurdles |
Asset Based Transactions, Distressed Restructurings, and IP Carve Outs
The rapid contraction of venture runways has driven a surge in special situations, restructurings, and intellectual property carve outs, with distressed assets accounting for 20% to 30% of total European healthtech M&A volume. When viable point products exhaust their capital reserves without access to bridge facilities, founder bankers structure accelerated asset sales out of formal administration or insolvency, isolating valuable proprietary code and customer contracts from historical operational liabilities.
The fragility of operationally heavy digital health businesses was illustrated by the collapse of Babylon Health. Despite securing a multi billion dollar valuation during its 2021 SPAC transaction, Babylon's unviable unit economics and excessive cash burn forced its domestic UK operations into formal administration. Corporate restructuring advisors and administrators executed an emergency asset fire sale of its primary UK clinical operating asset, GP at Hand, to US digital healthcare company eMed. Although common and early venture shareholders experienced a total equity write off, the asset purchase ring fenced operational risk, secured continuous primary care for hundreds of thousands of NHS patients, and preserved the core software assets.
Similarly, hardware-enabled digital medical platforms have proved vulnerable to financing contractions due to extensive inventory carrying costs, capital-intensive manufacturing requirements and extended regulatory verification cycles. Munich based automated digital pathology startup Inveox entered preliminary insolvency proceedings in late 2024 following the failure of an institutional funding round. Restructuring advisors engineered an asset deal out of insolvency, transferring the patented automation hardware, diagnostic IP, and core technical staff to an incoming investor group free from historical liabilities, preserving the technological asset while leaving legacy equity holders wiped out.
Beyond distressed environments, programmatic carve-outs are utilised by late-stage unicorns seeking to prune non-core operations. In France, precision medicine unicorn Owkin completed the carve-out of Waiv, its digital pathology diagnostics business, securing dedicated growth financing from an institutional investor consortium including Alpha Intelligence Capital, OTB, Karista, and Serena. Founder bankers structure these transactions by drafting Transition Services Agreements (TSAs), defining proprietary software IP boundaries, separating clinical datasets, and establishing clean corporate structures attractive to new growth capital.
Structured Secondaries and Continuation Vehicles
Given prolonged illiquidity in European public markets, secondary capital structures have evolved from exceptional measures into standardised portfolio liquidity solutions. General Partners (GPs) of venture funds face growing demands from institutional LPs seeking distributions. Founder bankers and secondary advisors structure GP-led continuation funds, enabling sponsors to transfer mature, high-performing healthcare platforms from older fund vintages into newly capitalised special purpose vehicles (SPVs) funded by secondary investors.
This vehicle provides liquidity to legacy LPs seeking to exit, while granting high-conviction assets extended operational runway and fresh capital to execute strategic roll-ups under the same management team. European private capital platforms have completed major continuation transactions, including Lakestar's $265 million continuation vehicle, Main Capital Partners' €520 million fund, and Bregal Unternehmerkapital's €811 million multi-asset continuation vehicle co-led by Pantheon.
Secondary transactions are also deployed to reset capitalization tables and facilitate partial liquidity for founders and early key employees. In mature scale-ups, founder bankers establish secondary tender offers at market-clearing pricing to align expectations without executing a dilutive primary down-round. Secondary transactions completed for Doctolib in early 2026 cleared at an implied enterprise valuation of approximately €3.6 billion, resetting equity benchmarks from its peak 2022 valuation of €5.8 billion while providing early investors and founders liquidity and reorganising the cap table for institutional stability.
Valuation Multiples, Regulatory Moats and Contractual Terms
Valuation models across European healthtech have disconnected from broad enterprise software benchmarks, shifting toward a rigorous evaluation of regulatory moats, clinical validation, and defensible unit economics.
HealthTech Sub-Sector | EV / NTM Revenue Multiple | EV / LTM EBITDA Multiple | Core Operational Value Drivers & Strategic Rationale |
Premium AI & Clinical Data Platforms | 6.0x – 8.0x+ | 15x – 18x+ | Proprietary, curated, and annotated clinical training datasets; interpretable algorithms compliant with EU AI Act; demonstrated "Rule of 40" operating profile |
Value-Based Care (VBC) Platforms | 5.5x – 7.0x | 12x – 15x | Contractually verified medical cost savings; demonstrable actuarial ROI for private payers or public healthcare authorities; high patient cohort retention |
General HealthTech / EHR SaaS | 4.0x – 6.0x (Avg: ~4.8x) | 10x – 13x | High Net Revenue Retention (NRR > 115%); low recurring revenue churn; mission-critical hospital or clinic workflow integration; predictable unit economics |
MedTech Hardware (MDR-Ready) | 3.5x – 5.5x | 11x – 14x | Secured EU Medical Device Regulation (MDR) or IVDR CE-mark certification; deep patent protection moats; high switching costs within clinical settings |
Consumer Health & Digital Wellness | 2.0x – 4.0x | 8x – 11x | Elevated customer acquisition costs (CAC); exposure to discretionary household spending; variable cohort retention; limited direct clinical reimbursement |
Regulatory Moats as Strategic Valuation Drivers
Regulatory approvals in Europe have transformed from operational hurdles into primary enterprise valuation drivers. Under the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), obtaining CE-mark certification requires extensive clinical evaluations, audited quality systems, and post-market clinical follow-up. Startups possessing fully certified MDR portfolios command premium valuations from international acquirers, as these certificates represent defensible barriers to entry that protect market share against non-compliant competitors.
Concurrently, the implementation of the European Union Artificial Intelligence Act (EU AI Act) has placed a premium on transparency and governance. Clinical artificial intelligence systems categorized as high-risk under Article 6 must demonstrate rigorous algorithmic explainability, continuous human oversight, mitigation of data bias in training models, and automated audit logging. Founder bankers actively position compliant, "glass-box" AI platforms as de-risked assets that command 20% to 30% valuation premiums over opaque, "black-box" alternatives, which carry significant remediation and regulatory enforcement liabilities.
Contractual Structuring: Price Mechanics, W&I Insurance, and Earn-Outs
The realisation of net transaction proceeds by selling shareholders is determined by the financial and legal mechanics embedded within the Sale and Purchase Agreement (SPA). Founder bankers employ sophisticated structural terms to protect realized value against buyer manipulation.
Pricing mechanisms in European transactions have heavily converged around the "Locked Box" model, adopted in roughly 82% of European private equity buyouts and 60% of general corporate transactions. Under a locked box, enterprise value is fixed based on a historic, audited balance sheet established prior to signing, transferring economic risk and operational upside to the buyer from that locked box date. To compensate selling shareholders for value generated between the locked box date and actual closing, founder bankers negotiate a "value ticker"—a cash interest rate accruing to equity holders at 3% to 6% per annum.
This locked box approach eliminates the post-closing vulnerability associated with US-style "Completion Accounts," where the purchase price is adjusted 60 to 120 days post-closing based on net working capital pegs and closing debt true-ups. Completion accounts leave founders exposed to post-acquisition accounting policy arbitrage and arbitrary working capital write-downs by buyers, making locked boxes the preferred structure in the European mid-market.
Structural Dimension | Locked Box Mechanism | Completion Accounts Mechanism | Market Implications for Founders |
Pricing Certainty | Fixed at signing based on historic audited balance sheet | Variable; subject to post-closing audit (60–120 days) | Locked box eliminates post-closing price risk and working capital disputes |
Interim Value Accretion | Captured via a negotiated "Value Ticker" (3%–6% p.a.) | Captured via closing balance sheet cash and NWC true-up | Ticker guarantees daily value accretion to sellers regardless of buyer cash utilization |
Working Capital Risk | Shifts to buyer on the Locked Box date | Borne by seller until closing; compared against an agreed "Peg" | Completion accounts leave sellers vulnerable to aggressive buyer inventory/bad-debt write-downs |
European PE Adoption | ~82% in PE buyouts; ~60% in general corporate M&A | ~18% in PE buyouts; standard in US cross-border deals | European sponsors strongly prefer locked boxes for clean, immediate distributions to LPs |
To maximise cash at close, founder bankers routinely mandate buy-side Warranty and Indemnity (W&I) insurance. In the European upper-mid-market (€100M+ EV), W&I penetration exceeds 80% for private equity exits. By shifting operational warranty risks to commercial underwriters, the seller's aggregate liability under the SPA is capped nominally at €1 or 0.5% of transaction enterprise value (representing the insurance policy retention/deductible). This mechanism eliminates the traditional requirement to place 5% to 15% of total purchase consideration into an indemnity cash escrow for 12 to 24 months, enabling immediate and clean distributions to founders and fund LPs.
Where valuation spreads cannot be bridged by fixed cash, earn-outs are incorporated into roughly 25% of European transactions, representing between 22% and 28% of total deal consideration. In healthtech transactions, founder bankers negotiate earn-out structures around binary clinical and regulatory milestones rather than subjective financial metrics. Tying deferred payouts to achieving FDA 510(k)/PMA clearance, completing clinical trial endpoints, obtaining MDR certification, or securing national reimbursement codes (such as DiGA inclusion) insulates founders from post-closing accounting disputes.
When financial earn-outs are unavoidable, advisory teams insist on top-line revenue metrics rather than EBITDA. Revenue metrics prevent acquirers from suppressing earn-out payouts through corporate overhead allocations, shared integration costs, or accounting manipulations. Furthermore, founder bankers negotiate operational covenants governed by an objective "Commercially Reasonable Efforts" (CRE) standard, benchmarked against industry-wide practices rather than an acquirer's internal priorities, while securing guaranteed annual R&D budgets and anti-cannibalization protections to ensure the target business is supported post-acquisition.
Strategic Implications and Ecosystem Outlook
The structural changes occurring across the European healthcare technology advisory and M&A market indicate that the founder-banker model represents an institutional response to systemic sector complexity rather than a temporary cyclical adjustment. The historical paradigm of treating digital health assets as standard enterprise software has concluded; clinical workflow integration, patient data privacy, multi-jurisdictional reimbursement pathways, and pan-European regulatory mandates present operational nuances that horizontal corporate finance cannot adequately evaluate.
A primary consequence of this realignment is the convergence of venture capital and private equity strategies. Well-capitalized venture scale-ups and mid-market private equity funds are operating with overlapping consolidation playbooks. Late-stage scale-ups execute synthetic platform roll-ups through share-for-share V2V acquisitions, utilizing their equity to aggregate fragmented point solutions while conserving capital. Concurrently, mid-market PE sponsors are acquiring early-stage Series A and Series B assets at compressed valuations, applying operational discipline, overhead rationalisation, and technological modernisation to engineer integrated, high-margin healthcare IT platforms.
Simultaneously, the European regulatory stack has evolved into a high-yield strategic asset. While the stringent demands of MDR, IVDR, and the EU AI Act increase initial time-to-market and demand disciplined capital allocation, companies that systematically clear these hurdles establish defensible commercial moats. International acquirers, particularly US-based strategic buyers and global healthcare conglomerates seeking to enter Europe, will increasingly utilise targeted M&A to acquire certified regulatory assets and validated clinical datasets as a lower-risk alternative to navigating multi-year compliance timelines organically.
These industry dynamics have institutionalized the operator-dealmaker advisory model across Europe. Transactions in the lower-to-mid-market tier between €25 million and €250 million enterprise value will remain the core domain of specialist founder-banker boutiques, whose combination of transaction structuring, clinical fluency, and founder credibility bridges the gap between capital market expectations and clinical execution.
As European healthcare technology progresses through this period of disciplined consolidation, liquidity generation will depend on rigorous transaction structuring. Whether executing synthetic share swaps, structuring private equity rollover waterfalls, carving out distressed IP assets, or establishing secondary continuation vehicles, founder bankers provide the transactional architecture required to navigate a demanding capital environment, ensuring the European digital health ecosystem transitions into sustainable industrial maturity.
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Healthcare.Digital serves as a research platform for Nelson Advisors’ perspectives on deals, valuations and structural shifts reshaping Global Digital Health, MedTech, Healthcare AI and Health IT. https://www.healthcare.digital
Nelson Advisors is one of Europe's leading mergers and acquisitions advisory firms, exclusively dedicated to the dynamic and rapidly evolving healthcare technology sector. With a deep understanding of market dynamics and technological advancements, they empower innovative HealthTech companies and strategic investors to navigate complex transactions and achieve their growth ambitions. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA. #Canada #Commonwealth #CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #Genomics
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments